These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 27603297)
1. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. Wauters L; Billiet T; Papamichael K; Ballet V; Joniau S; Verschueren P; Silversmit G; Van Assche G; Vermeire S; Ferrante M Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):84-90. PubMed ID: 27603297 [TBL] [Abstract][Full Text] [Related]
2. Better survival of renal cell carcinoma in patients with inflammatory bowel disease. Derikx LA; Nissen LH; Drenth JP; van Herpen CM; Kievit W; Verhoeven RH; Mulders PF; Hulsbergen-van de Kaa CA; Boers-Sonderen MJ; van den Heuvel TR; Pierik M; Nagtegaal ID; Hoentjen F; ; ; Oncotarget; 2015 Nov; 6(35):38336-47. PubMed ID: 26447542 [TBL] [Abstract][Full Text] [Related]
3. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden. Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144 [TBL] [Abstract][Full Text] [Related]
4. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413 [TBL] [Abstract][Full Text] [Related]
5. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331 [TBL] [Abstract][Full Text] [Related]
6. Frequency and associated factors of hair loss among patients with inflammatory bowel disease. Shah R; Abraham B; Hou J; Sellin J World J Gastroenterol; 2015 Jan; 21(1):229-32. PubMed ID: 25574095 [TBL] [Abstract][Full Text] [Related]
7. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515 [TBL] [Abstract][Full Text] [Related]
8. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825 [TBL] [Abstract][Full Text] [Related]
9. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists. Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266 [TBL] [Abstract][Full Text] [Related]
11. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059 [TBL] [Abstract][Full Text] [Related]
12. Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy. van Gennep S; Sahami S; Buskens CJ; van den Brink GR; Ponsioen CY; D'Hoore A; de Buck van Overstraeten A; van Assche G; Ferrante M; Vermeire S; Bemelman WA; D'Haens GR; Löwenberg M Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):338-344. PubMed ID: 27902515 [TBL] [Abstract][Full Text] [Related]
13. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor. Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784 [TBL] [Abstract][Full Text] [Related]
14. Incidence, management, and course of cancer in patients with inflammatory bowel disease. Algaba A; Guerra I; Marín-Jiménez I; Quintanilla E; López-Serrano P; García-Sánchez MC; Casis B; Taxonera C; Moral I; Chaparro M; Martín-Rodríguez D; Martín-Arranz MD; Manceñido N; Menchén L; López-Sanromán A; Castaño Á; Bermejo F J Crohns Colitis; 2015 Apr; 9(4):326-33. PubMed ID: 25687203 [TBL] [Abstract][Full Text] [Related]
15. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181 [TBL] [Abstract][Full Text] [Related]
16. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. Nyboe Andersen N; Pasternak B; Basit S; Andersson M; Svanström H; Caspersen S; Munkholm P; Hviid A; Jess T JAMA; 2014 Jun; 311(23):2406-13. PubMed ID: 24938563 [TBL] [Abstract][Full Text] [Related]
18. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938 [TBL] [Abstract][Full Text] [Related]
19. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort. Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S; J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916 [TBL] [Abstract][Full Text] [Related]
20. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]